Ai Mediq offers the world’s first Medical Device for providing
individualised, biofeedback-controlled Intermittent Hypoxia-Hyperoxia
ReOxy is the only medical IHHT device in the world which is regulatory
approved (TUV Rheinland) and CE-marked for professional healthcare use.

Our advantages


ReOxy® offers innovative solution that improves quality of life and well- being of patients, but can also enhance fitness of healthy individuals. ReOxy® safely increases physical capacity even without doing exercise, and improves cardiovascular risk factors profile in individuals including seniors, patients with severely decreased functional capabilities, and the disabled. Being a breathing therapy that does not require performing any physical exercise, ReOxy treatment has no limitations associated with exercise, and is free of exercise-related adverse events.

Healthcare Provider

ReOxy is the first medical IHHT device for professional health care market which is commercially available worldwide. The personalised approach it employs allows using the IHHT method in patients of various age, sex and nosology groups, including seniors with dementia and frailty, and other patients with apparent physical limitations. ReOxy® represents not only the most clinically effective solution for this type of patients: it is also the most cost-effective.

Doctor (or Practitioner)

ReOxy is easy-to-use: built-in intelligent software automatically calculates the starting procedure parameters based upon the results of a pre-treatment hypoxic test, and then controls and adjusts them in real- time during the whole treatment session to ensure high effectiveness and safety of the treatment. Competent technical and scientific support is available 24/7 by phone, email and popular instant messengers.


Strategic location of our distribution center enables shipment of Ai Mediq products to any part of the world within 48 hours. Competent technical and scientific support is available 24/7 by phone, email and popular instant messengers. Flexible terms for all distributor types. On- and off-site training options for distributor personnel. Comprehensive marketing materials.


Ai Mediq is a Luxembourg-based ground-breaking medical technology company
that develops novel non-invasive therapeutic solutions leveraging
positive treatment effects of high altitude (hypoxic) exposure, medical
devices for Intermittent Hypoxic Treatment, and medical software
algorithms for its personalisation.

Read more

OUR Partners

Manufacturing partner

ReOxy breathing therapy device is a device that was developed based on latest developments in medical devices and electronics.

ReOxy is manufactured by Bitmos GmbH and is CE marked and produced in full compliance to 93/42/EEC (Medical Devices Directive – MDD), facilitating high quality and safety of operation.

Clinical partners

To help us carry out our mission to provide our customers with innovative solutions that are vital to patient care, we continue to work with a variety of partners to develop and introduce leading edge technologies and products.


Medica 2019

Ai Mediq is looking forward to seeing all our existing partners and new potential collaborators at joint booth of Ministry of Economy of Grand Duchy of Luxembourg. The booth number remained the same B70 in Hall 3, so you should have no problems locating us. See you in Dusseldorf. P.S. Distributors wanted.

Read More

Cardiac Rehabilitation of Elderly – New Trial in Italy

Last Friday (26th of July 2019) one of the most recent clinical trials involving ReOxy has been registered with database with NCT04034082 identifier.

Read More

New clinical trial in CHF patients

Ai Mediq is pleased to announce approval of new clinical trial named "Evaluation of clinical efficacy of interval hypoxic-hyperoxic trainings in treatment of patients with reduced ejection fraction of left ventricle (2-3 NYHA)

Read More

ESC Congress 2019 combined with WCC2019 in Paris

Ai Mediq is pleased to announce participation in the annual meeting of European Society of Cardiology (ESC Congress) 2019 which will take place this time in Paris, France. For the first time ...

Read More
All news